Purpose of review: This overview discusses several important developments in testicular germ cell tumors (TGCTs) over the past year.
Recent findings: Genomic studies continue to investigate gene expression as possible markers for disease relapse and metastatic potential. Optimal treatment strategies for early-stage seminomas continue to evolve toward surveillance versus chemotherapy, although developing radiation delivery modalities may ultimately provide a safe alternative. The role of retroperitoneal lymph node dissection in postorchiectomy early-stage nonseminoma germ cell tumors remains a topic of debate.
Summary: Treatment paradigms continue to be refined for TGCTs as research in these areas continues.